Quantcast

Latest Clinical trial Stories

2014-10-09 23:06:16

Provectus Biopharmaceuticals Collaborates with ERT’s COA Experts to Understand Patient Perspective during Melanoma Drug Development PHILADELPHIA, PA (PRWEB) October 09, 2014 ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced that Provectus Biopharmaceuticals (NYSE MKT: PVCT) is collaborating with ERT’s Clinical Outcome Assessment (COA) consultants on their Phase III trial of agent PV-10 for intralesional (IL)...

2014-10-09 08:27:14

NASDAQ: NVCNTSX: NVC VANCOUVER, Oct. 9, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara(TM) transcatheter mitral valve. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted to...

2014-10-08 23:10:52

Latest Version of Electronic Data Capture (EDC) ClinCapture® Offers Drag and Drop Features, and is World’s Only Fully Free, Validated EDC System Sunnyvale, CA (PRWEB) October 08, 2014 Technology led CRO and software vendor Clinovo introduces new self-service features to ClinCapture, a leading Electronic Data Capture (EDC) system. Now for the first time, sponsor companies can avoid costly professional services and fully control the development, distribution, and budgeting of their...

2014-10-08 23:08:06

SureClinical, National Cancer Institute, ACT Oncology and CareLex to discuss how the draft OASIS eTMF Standard Can Enhance Clinical Trial Efficiency and Quality Rancho Cordova, California (PRWEB) October 08, 2014 DIA and SureClinical will co-host the complimentary webinar "How New Electronic Trial Master File (eTMF) Data Standards Can Enhance Clinical Trial Efficiency and Quality" on October 28 from 11 a.m. to 12:15 p.m. EDT.     In addition to DIA and...

2014-10-08 08:27:59

New Device Featured at the European Academy of Dermatology and Venereology* WAYLAND, Massachusetts, October 8, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay(TM) picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with...

2014-10-08 08:27:11

ALISO VIEJO, Calif., Oct. 8, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from the phase II trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD) and the results of the phase IV PRISM II study evaluating NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) for the treatment of pseudobulbar affect (PBA) in patients with AD will be presented at the American Neurological Association's (ANA)...

2014-10-08 08:26:58

NORTHBROOK, Ill., Oct. 8, 2014 /PRNewswire/ -- Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa. http://photos.prnewswire.com/prnvar/20140416/84970 The data assessed the efficacy and safety of isavuconazole in the treatment of patients with invasive mucormycosis (n=37) enrolled in the open-label,...

2014-10-08 08:25:59

SANTA ROSA, Calif., Oct. 8, 2014 /PRNewswire/ -- Ruthigen Inc. (NASDAQ: RTGN), a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal...

2014-10-07 16:26:23

WASHINGTON, Oct. 7, 2014 /PRNewswire-USNewswire/ -- Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, "Researching Cancer Medicines: Setbacks and Stepping Stones," which highlights the number of investigational cancer medicines that did not succeed in clinical trials and how these so-called "failures" are a critical part of the drug development process. http://photos.prnewswire.com/prnvar/20091027/PHRMALOGO The report illustrates the immense...

2014-10-07 08:28:56

MARLBOROUGH, Mass., Oct. 7, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.